Feb. 17 at 3:00 PM
Masimo shares surged about 34% after agreeing to be acquired by Danaher for
$180 per share in cash, valuing the deal at roughly
$9.9 billion. The offer represents a significant premium to Masimo’s prior market value of about
$7 billion.
Danaher, which provides tools and equipment to the biotech, life sciences, and diagnostics industries, said Masimo’s patient-monitoring technologies — including pulse oximetry — will strengthen its diagnostics segment. Masimo will operate as a standalone unit within that division.
The acquisition is expected to be immediately accretive, adding 15 to 20 cents to Danaher’s adjusted earnings per share in the first full year, and about 70 cents by year five. Masimo generated
$1.52 billion in revenue in 2025, up 9%, and is projected to produce more than
$530 million in EBITDA by 2027. Danaher also expects over
$125 million in annual cost savings by the fifth year after closing.
$MASI $DHR